Nodular Sclerosis Hodgkin Lymphoma (C81.1)

Name of the Condition

• Common Name: Nodular Sclerosis Hodgkin Lymphoma
• Medical Terms: Nodular Sclerosis Hodgkin's Disease, NSHL

Summary

Nodular sclerosis Hodgkin lymphoma (NSHL) is a subtype of Hodgkin lymphoma characterized by the presence of Reed-Sternberg cells and a fibrous (sclerotic) nodular pattern in affected lymph nodes. It is the most common subtype of Hodgkin lymphoma and typically presents with painless lymph node enlargement, often in the mediastinum or neck. NSHL tends to affect young adults and has a favorable prognosis with standard treatment.

Causes

The exact cause of NSHL is not fully understood, but it is believed to result from a combination of genetic and environmental factors. Viral infections, such as Epstein-Barr virus (EBV), may contribute to its development, though not all cases are associated with EBV. Genetic predisposition and immune system interactions are also thought to play a role.

Risk Factors

• Age: Most commonly diagnosed in young adults (15-35 years) and adolescents.
• Gender: Slightly more prevalent in females.
• Family History: Having a first-degree relative with lymphoma may increase risk.
• Epstein-Barr Virus: Prior infection may elevate susceptibility.

Symptoms

• Painless swelling of lymph nodes, often in the neck, armpits, or chest.
• Persistent fatigue or weakness.
• Unexplained fever or night sweats.
• Unintended weight loss.
• Itchy skin (pruritus).
• Cough or shortness of breath (if mediastinal nodes are involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation and laboratory tests. A physical examination identifies enlarged lymph nodes, followed by imaging (e.g., CT, PET) to assess disease extent. A lymph node biopsy is required to confirm the presence of Reed-Sternberg cells and the nodular sclerosis pattern. Bone marrow biopsy may be performed to rule out spread.

Treatment Options

Treatment depends on disease stage and may include chemotherapy (e.g., ABVD regimen), radiation therapy, or a combination. Early-stage disease often responds well to limited radiation, while advanced stages may require multi-agent chemotherapy. Stem cell transplantation is considered for relapsed or refractory cases.

Prognosis and Follow-Up

NSHL has a high cure rate, especially in early stages. Long-term survival rates exceed 90% for localized disease. Follow-up includes regular imaging and clinical assessments to monitor for recurrence. Late effects, such as secondary cancers or cardiovascular issues, may occur with treatment and require ongoing surveillance.

Complications

• Recurrence of lymphoma.
• Treatment-related toxicities (e.g., infertility, heart or lung damage).
• Secondary malignancies (e.g., leukemia, breast cancer).
• Infection risk due to immunosuppression.

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health.
• Avoid tobacco and limit alcohol to reduce secondary cancer risk.
• Stay up-to-date with vaccinations (e.g., flu, pneumonia) to prevent infections.
• Discuss fertility preservation with your care team before treatment.

When to Seek Professional Help

Seek medical attention if you experience persistent, painless lymph node swelling, unexplained weight loss, night sweats, or fatigue. Prompt evaluation is important for early diagnosis and treatment.

Tips for Medical Coders

Code C81.1 is specific to nodular sclerosis Hodgkin lymphoma. Documentation should specify the subtype and site (e.g., mediastinal, cervical) when available. Ensure biopsy results or pathology reports confirm the nodular sclerosis pattern to support accurate coding. Avoid using this code for other Hodgkin lymphoma subtypes or non-Hodgkin lymphomas.